Adherence to Quality of Care Indicators and Location of Sickle Cell Care Within Indiana
Newborn screening (NBS) follow-up programs for infants with sickle cell disease (SCD) are highly variable among states. Initiated in 2009, Sickle SAFE, the NBS follow-up program for infants with SCD in Indiana, follows infants through home visits and phone contact. The current study assessed the attainment rates for recently published quality indicators of pediatric SCD care for Sickle SAFE participants. Using retrospective data, we determined the proportion of children who received transcranial Doppler (TCD) screening, influenza, and pneumococcal vaccination and were prescribed hydroxyurea. We calculated the mean age at confirmatory testing, time to receipt of penicillin prophylaxis, and mean age when genetic counseling was offered. One hundred ninety-eight children born with SCD in Indiana between July 1, 2009 and June 30, 2017 were followed for at least 1 year. While 97.5% received at least one dose of conjugated pneumococcal vaccine, vaccination with the 23 valent pneumococcal vaccine varied by location (county) of care (Allen: 14.3%, Lake: 26.7%, St. Joseph: 40.0%, Marion: 73.3%). Overall TCD screening rate for eligible children was 53%; TCD screening rate varied widely by location of care (Lake: 25% vs. Marion: 63.8%). Similarly, hydroxyurea prescribing practices varied significantly by location of care (p < 0.001). Identified gaps in adherence to quality indicators in SCD care will serve as the basis for future quality improvement initiatives.
KeywordsSickle cell disease Newborn screening Penicillin prophylaxis Hydroxyurea Transcranial Doppler
The Sickle SAFE program is funded by the Indiana State Department of Health, Maternal Child Health Division’s Genomics and Newborn Screening Program.
Compliance with Ethical Standards
Conflict of interest
Dr. Meier is a consultant for CVS Caremark and receives grant funding from the Indiana State Department of Health. The other authors have no conflicts to disclose.
- 2.National Heart Lung and Blood Institute (NHLBI) (2014). Evidence-based management of sickle cell disease: expert panel report, 2014. Retrieved May 15, 2019, from http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.
- 3.Adamkiewicz, T. V., Sarnaik, S., Buchanan, G. R., et al. (2003). Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. Journal of Pediatrics, 143(4), 438–444.CrossRefGoogle Scholar
- 6.Kavanagh, P. L., Wang, C. J., Therrell, B. L., Sprinz, P. G., & Bauchner, H. (2008). Communication of positive newborn screening results for sickle cell disease and sickle cell trait: Variation across states. American Journal of Medical Genetics C, 148(1), 15–22. https://doi.org/10.1002/ajmg.c.30160.CrossRefGoogle Scholar
- 7.Wang, C. J., Kavanagh, P. L., Little, A. A., Holliman, J. B., & Sprinz, P. G. (2011). Quality-of-care indicators for children with sickle cell disease. Pediatrics, 128(3), 484–493.Google Scholar
- 8.Indiana State Department of Health. Indiana Vital Statistics. Retrieved from http://www.stats.indiana.edu/vitals/. Accessed October 25, 2018.
- 9.United States Census Bureau Quick Facts Indiana, United States. 2018. Washington, DC: Department of Commerce. Retrieved from https://www.census.gov/quickfacts/fact/table/indianapoliscitybalanceindiana,US/PST045218. Accessed October 25, 2018.
- 10.United States Census Bureau Urban and Rural Classification and Urban Area Criteria (2010). Washington, DC: Department of Commerce. Retrieved from https://www.census.gov/programs-surveys/geography/guidance/geo-areas/urban-rural/2010-urban-rural.html. Accessed October 25, 2018.
- 11.Streetly, A., Sisodia, R., Dick, M., Latinovic, R., Hounsell, K., & Dormandy, E. (2018). Evaluation of newborn sickle cell screening programme in England: 2010–2016. Archives of Disease in Childhood, 103(7), 648–653.Google Scholar
- 12.Centers for Disease Control and Prevention Estimates of Flu Vaccination Coverage among Children—United States, 2017–2018 Flu Season. Retrieved from https://www.cdc.gov/flu/fluvaxview/coverage-1718estimates-children.htm. Published 2018. Accessed November 14, 2018.
- 14.Steinberg, M. H., McCarthy, W. F., Castro, O., et al. (2010). The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. American Journal of Hematology, 85(6), 403–408.Google Scholar
- 18.Rogers, Z. R. (1997). Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Seminars in Hematology, 34(3 Suppl 3), 42–47.Google Scholar